On June 17, Edwards Lifesciences rose 3.51% in regular trading, trading at $89.31/share, with turnover of $257 million. The rally was driven by the Centers for Medicare & Medicaid Services releasing a Proposed Decision Memo for a National Coverage Determination on transcatheter aortic valve replacement procedures.

RBC Capital Markets had previously identified the TAVR NCD memo as a notable upcoming catalyst for Edwards Lifesciences and the broader TAVR space. RBC's physician checks suggest coverage changes could drive approximately 5% growth in national procedure volumes, with the single-operator model shift being the most impactful component for procedure efficiency, along with site-of-service expansion. Combined with the ACC/AHA guideline update, RBC sees a favorable setup for TAVR growth acceleration into 2027.

Within the Health Care Equipment sector, Abbott Laboratories rose 1.12%, Medtronic rose 1.0%, Stryker gained 0.52%, Intuitive Surgical added 0.18%, while Boston Scientific declined 0.3%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)